Literature DB >> 9712100

Spondyloarthropathy and human immunodeficiency virus infection in Zambia.

P Njobvu1, P McGill, H Kerr, J Jellis, J Pobee.   

Abstract

OBJECTIVE: To explore the relationship between spondyloarthropathy (SpA) and infection with the human immunodeficiency virus (HIV) in black Zambians.
METHODS: Consecutive patients attending an arthritis clinic in a 30 month period were assessed clinically and tested for the presence of antibodies to HIV. HLA-B27 gene was investigated by polymerase chain reaction and T cell subsets were tested in selected subgroups.
RESULTS: Of 595 new attendees, 272 were diagnosed with SpA [130 reactive arthritis (ReA), 128 undifferentiated SpA (uSpA), 13 psoriatic arthritis (PsA), 1 ankylosing spondylitis] and 146 with a reactive type arthritis alone (AA) without preceding clinical trigger infection or SpA features. HIV seroprevalence was 98% in uSpA, 94% PsA, 87% ReA, 64% AA; vs approximately 50% among hospital outpatients and 30% of the adult urban population. Prevalence of SpA is calculated at approximately 180/100,000 in HIV positive and approximately 15/100,000 in HIV negative in the general population. Dysentery was the most common identified trigger. Positive HIV status correlated strongly with SpA features and aggressive sustained disease. At onset 80% of patients were in WHO clinical stage 1 (no disease or lymphadenopathy alone), with a mean CD4+ count of 279/microl. Stage 4 patients had a mean CD4+ count of 60/microl and inactive arthritis. The B27 gene was absent in 30 patients tested.
CONCLUSION: ReA is the most common inflammatory joint disorder in black Zambians and is closely linked to HIV infection and not B27, even though our subjects had clinical and radiological characteristics similar to those reported in HLA-B27 positive Caucasians. The changing epidemiology of SpA in this region has important practical and educational implications.

Entities:  

Mesh:

Year:  1998        PMID: 9712100

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  HIV infection and ankylosing spondylitis. Which benefits from the coexistence?

Authors:  N V Sipsas; G D Panayiotakopoulos; A Zormpala; T Kordossis
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

Review 2.  Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review.

Authors:  Telma Thrastardottir; Thorvardur Jon Love
Journal:  Rheumatol Int       Date:  2017-11-09       Impact factor: 2.631

Review 3.  When is arthritis reactive?

Authors:  S S Hamdulay; S J Glynne; A Keat
Journal:  Postgrad Med J       Date:  2006-07       Impact factor: 2.401

4.  Early diagnosis and treatment of ankylosing spondylitis in Africa and the Middle East.

Authors:  Bahiri Rachid; Bassel El Zorkany; Ehab Youseif; Mohammed Tikly
Journal:  Clin Rheumatol       Date:  2012-08-19       Impact factor: 2.980

Review 5.  Spondyloarthritis in sub-Saharan Africa.

Authors:  Mohammed Tikly; Panganani Njobvu; Paul McGill
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.592

Review 6.  Psoriatic arthritis epidemiology.

Authors:  Arathi R Setty; Hyon K Choi
Journal:  Curr Rheumatol Rep       Date:  2007-12       Impact factor: 4.592

Review 7.  The ramifications of HLA-B27.

Authors:  Nicholas J Sheehan
Journal:  J R Soc Med       Date:  2004-01       Impact factor: 18.000

8.  Clinical and epidemiological features of rheumatic diseases in patients attending the university hospital in Kinshasa.

Authors:  J J Malemba; J M Mbuyi-Muamba
Journal:  Clin Rheumatol       Date:  2007-06-02       Impact factor: 3.650

9.  Clinical patterns of juvenile idiopathic arthritis in Zambia.

Authors:  James Chipeta; Panganani Njobvu; Somwe Wa-Somwe; Chifumbe Chintu; Paul E McGill; Richard Bucala
Journal:  Pediatr Rheumatol Online J       Date:  2013-09-14       Impact factor: 3.054

10.  Evolution of the global burden of viral infections from unsafe medical injections, 2000-2010.

Authors:  Jacques Pépin; Claire Nour Abou Chakra; Eric Pépin; Vincent Nault; Louis Valiquette
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.